Humira(Cf) Pen(Adalimumab)
Medicare prescription drug cost, prescriptions and prescribers, 2024
$4.33B
Medicare cost, 2024
$4.33B
Medicare cost, 2024
Medicare drug plans spent $4.3 billion on Humira(Cf) Pen (adalimumab) in 2024, for 490,135 prescriptions and refills filled by 63,749 patients. It ranks 9th among all drugs by Medicare drug plan spending. At about $8,828 per prescription it is a high-cost drug. New York accounts for the most spending ($314.9 million, 7% of the total).
Medicare cost, 2024
$4.33B
-2.1% from 2023
Prescriptions
490K
$8,828.43 per claim
Patients
64K
23,305 prescribers
Total spending, 2024
$4.33B
$67,881.99 per patient
Questions and answers
How much does Medicare spend on Humira(Cf) Pen?
Medicare prescription drug plans paid $4.33B for Humira(Cf) Pen in 2024, for 490,135 prescriptions and refills to 63,749 patients (down 2.1% from 2023). The average cost per claim was $8,828.43.
Which state spends the most on Humira(Cf) Pen?
New York had the highest Medicare cost for Humira(Cf) Pen in 2024: $314.9M for 34,468 claims, followed by Texas ($304.3M).
Who prescribes Humira(Cf) Pen the most?
Anne Marie Holly, physician assistant in Rochester, NY, had the highest Medicare cost for Humira(Cf) Pen in 2024: 902 claims costing $8.4M.
Spending over the years
Medicare spending by year
All plans and makers
Prescriber data: cost by year
Medicare spending on Humira(Cf) Pen was $4.33B in 2024, after a high of $4.42B in 2023.
By state
Where the prescribers practice, 2024
Medicare cost by state
States with the highest cost
Top prescribers of Humira(Cf) Pen, 2024
By Medicare drug cost
| Prescriber | Type | Claims | Patients | Cost |
|---|---|---|---|---|
| Anne Marie Holly Rochester, NY | Physician Assistant | 902 | 190 | $8.4M |
| Wilfredo A Villarrubia West Columbia, SC | Physician Assistant | 640 | 132 | $5.7M |
| Amanda L Matthews San Antonio, TX | Physician Assistant | 688 | 101 | $5.3M |
| Michael Babilonia Roman Mayaguez, PR | Internal Medicine | 734 | 68 | $5.1M |
| Bernard S Hojaili New Iberia, LA | Internal Medicine | 426 | 58 | $4.5M |
| Rajiv E Shah Winston Salem, NC | Ophthalmology | 595 | 69 | $4.3M |
| Gretchen J Crawford Tucson, AZ | Nurse Practitioner | 392 | 82 | $3.7M |
| Elvin R Garcia McAllen, TX | Rheumatology | 394 | 51 | $3.6M |
| Luis C Salayandia El Paso, TX | Rheumatology | 450 | 56 | $3.6M |
| Kayvan Kamali Longview, TX | Rheumatology | 495 | 69 | $3.4M |
| Ulker Tok Tucson, AZ | Rheumatology | 376 | 87 | $3.4M |
| Seleaina A Thomas Victorville, CA | Nurse Practitioner | 454 | 53 | $3.3M |
| Livia M Bermudez Fajardo, PR | Rheumatology | 469 | 57 | $3.2M |
| David G Stainbrook Jr. Du Bois, PA | Rheumatology | 322 | 38 | $3.2M |
| Shriram A Lokare Peoria, IL | Rheumatology | 414 | 55 | $3.1M |
| Jolanta Sobotka-Czarnecki Flint, MI | Rheumatology | 431 | 47 | $3.1M |
| Ruth A Wilson Lagrange, IN | Nurse Practitioner | 315 | 44 | $3.0M |
| Jorge A Mundo Humacao, PR | Rheumatology | 431 | 56 | $3.0M |
| Deya M Obaidat Indianapolis, IN | Rheumatology | 350 | 52 | $3.0M |
| Justina J Tseng Redding, CA | Rheumatology | 295 | 42 | $2.8M |
| Zaida Z Fuxench Lopez Bayamon, PR | Internal Medicine | 273 | 30 | $2.8M |
| Marlon J Navarro Eau Claire, WI | Rheumatology | 361 | 41 | $2.8M |
| Carl M Gauthier Jr. Hammond, LA | Rheumatology | 348 | 41 | $2.8M |
| Ashrito K Dayal Charlotte, NC | Rheumatology | 338 | 40 | $2.8M |
| Elizabeth Harding Charleston, SC | Physician Assistant | 144 | 19 | $2.7M |
Prescriber data by year
| Year | Prescribers | Claims | Patients | Cost |
|---|---|---|---|---|
| 2022 | 21,439 | 438,151 | 57,400 | $3.69B |
| 2023 | 22,806 | 478,675 | 61,455 | $4.42B |
| 2024 | 23,305 | 490,135 | 63,749 | $4.33B |
Makers, 2024
Spending by manufacturer as listed in the spending data
More drugs: Medicare drug spending and the Prescriptions view.
Official US government data on Medicare prescription drug plans (Part D) and Medicaid drug use. Cost and spending are before the rebates drug makers pay. Prescribers with fewer than 11 claims of the drug are not published.
Through September 2026, 716,864 side-effect reports named adalimumab, the active ingredient of Humira(Cf) Pen (reports from 1993 on). 367,566 of them (51.3%) were serious, 31,605 named a death and 152,383 named a hospital stay. The reactions named most often were drug ineffective, pain and arthralgia. 187,721 reports came in the last 5 years (since 2022).
How to read these numbers
- A report shows that a patient, doctor or drug company suspected a link. It does not prove that the drug caused the effect.
- Counts are not risk rates. They depend on how many people use the drug, how long it has been sold, news and reporting habits, so they do not show which drug is safer.
- The newest months are partial: reports keep arriving late.
Reports, all years
716,864
23,258 in 2025 (-20.8% from 2024)
Serious
51.3%
367,566 reports
Deaths named
31,605
4.4% of reports
Hospital stays
152,383
21.3% of reports
Reports by year
Serious reports include those that name a death, a hospital stay, a disability or another serious outcome.
Reports received by year
Since 2002. 2026 is the year so far.
Reports naming a death or a hospital stay
One report can name both
Reactions
Reactions named most often
All years. Share = part of all reports in that period. A report can name several reactions.
Patients
As given in the reports; many reports leave sex or age out.
Sex of the patient
All years
Age of the patient
Age when the effect started, all years
Questions and answers
How many side-effect reports name Humira(Cf) Pen?
716,864 reports from 1993 through September 2026 named adalimumab, the active ingredient of Humira(Cf) Pen. 367,566 of them (51.3%) were serious, 31,605 named a death and 152,383 named a hospital stay.
What are the most reported side effects of Humira(Cf) Pen?
92,932 reports named drug ineffective, the reaction named most often, followed by pain (50,798) and arthralgia (49,681). In the last 5 years the reaction named most often was drug ineffective (22,775 reports). A report can name several reactions.
How many side-effect reports named Humira(Cf) Pen in 2025?
23,258 reports were received in 2025 (-20.8% from 2024). 2026 so far: 12,817 reports through September 2026, and more keep arriving late.
Do side-effect reports prove that Humira(Cf) Pen caused a problem?
No. A report shows that a patient, doctor or drug company suspected a link; it does not prove that Humira(Cf) Pen caused the effect. Report counts depend on how widely a drug is used, how long it has been sold, news and reporting habits, so they are not risk rates and do not show which drug is safer.
Related pages
- Other Medicare drug pages with adalimumab: Humira Pen, Humira(Cf), Humira, Humira(Cf) Pen Crohn's-Uc-Hs, Humira(Cf) Pen Psor-Uv-Adol Hs, Humira Pen Crohn's-Uc-Hs, Humira Pen Psor-Uveits-Adol Hs, Humira(Cf) Pediatric Crohn's
- Makers on the stock market:
ABBV·ABBV drug pipeline - Drug approvals (1 approval on file for adalimumab) · Clinical trials · Medicare drug spending
Side-effect reports from official public data, counted per active ingredient (adalimumab) by the year the report was received, so the brand and generic pages of one ingredient show the same reports. A report can name several drugs and several reactions and counts for each. Reaction names are the standard medical terms used in the reports. Reports whose product could not be matched to a drug are not counted. Updated November 2026.